Bharat Biotech International Ltd on Tuesday announced the launch of Hillchol, a novel single-strain oral cholera vaccine.
A press release from the vaccine maker said Hillchol (BBV131) was developed by Bharat Biotech under licence from Hilleman Laboratories (funded by Merck USA and Wellcome Trust) to combat Cholera.
Global demand for Oral Cholera Vaccines (OCVs) exceeds 100 million doses annually, making them crucial for cholera control. Globally, there is a shortage of OCVs as there is only one manufacturer.
BBIL has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of Hillchol, it further said.
A multi-stage, clinical evolution process, culminating in a Phase 3 study confirmed the vaccine safety, immunogenicity and non-inferiority to existing OCVs, establishing its potential for white spirit, and public health use.
The vaccine, a single dose respule, is administered orally on day 0 and 14 and is suitable for individuals older than one year.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Featured Video Of The Day
JMM-Led INDIA Bloc Closes The Door For NDA In Jharkhand
Bharat Biotech Unveils Next-Gen Oral Cholera Vaccine To Address Global Health Gaps "Critical Shortage" Of Cholera Vaccine, Says WHO, Calls for Production Boost Cholera Vaccine Shortage Forces Move To Temporary One-Dose Strategy: WHO 3 Dead, Over 30 Cops Injured: Violence In UP's Sambhal Over Mosque Survey "Moving Towards One Party, One Nation": Uddhav Thackeray On BJP Victory After Mega Maharashtra Victory, NDA's Oath Ceremony Likely Tomorrow Autopsy Reveals Chilling Details Of Family Kidnapped, Killed In Manipur On "Bail Is Norm" Rule, Former Chief Justice UU Lalit Points To A Caveat Uruguay Votes For Next President In Razor-Sharp Election Track Latest News Live on NDTV.com and get news updates from India and around the world.